Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hiroki Shimoda
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research,
Institute of Science Tokyo
Observed institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research,
Institute of Science Tokyo
ORCID:
0009-0008-8758-776X
Observed ORCID:
0009-0008-8758-776X
OpenAlex ID:
A5129849475
Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum‐Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study
2026
·
Hiroki Shimoda
, Yuki Nakamura
, et al.
·
International Journal of Urology
·
1
Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma
2026
·
Hiroki Shimoda
, Noboru Numao
, et al.
·
Urologic Oncology Seminars and Original Investigations
Durable Disease Control With Nivolumab in Malignant Epithelioid Angiomyolipoma: A Case Report
2026
·
Hiroki Shimoda
, Shohei Fukuda
, et al.
·
IJU Case Reports
Show more works
View as search
Works count:
3
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type